[ad_1]
SINGAPORE (ANTARA/PRNewswire) — DKSH Healthcare Business Unit, a strategic healthcare solutions partner and leading provider of market expansion services to pharmaceutical, OTC, consumer health and medical device companies, has entered into a partnership with Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151, President and CEO: Masashi Miyamoto), a global specialty pharmaceutical company headquartered in Japan, in line with Kyowa Kirin’s announced business transformation plan for the Asia Pacific region. The scope of the partnership includes a promotion and distribution agreement for commercial rights of Kyowa Kirin’s established pharmaceutical portfolio in Korea, Taiwan, Singapore, Thailand, Malaysia and Hong Kong and Macau SARs, as well as global products – Crysvita® in Singapore, Thailand, Malaysia and Hong Kong and Macau SARs, and Poteligeo ® in Singapore.
Recognized for providing a full range of integrated solutions to support the sustainable development of client partners, DKSH was selected by Kyowa Kirin as a strategic partner to implement a full agency alliance business model to provide end-to-end healthcare solutions that prioritizes patients’ access to healthcare. With DKSH’s deep expertise in nephrology, strong distribution network and strong commercial capabilities, this collaboration is an important step forward in the continued provision of patient care and medical services in the region.
Dr. Abdul Mullick, Chief International Business Officer (CIBO) of Kyowa Kirin, said: “We are confident in embarking on this new journey together with DKSH. Given DKSH’s proven healthcare expertise and commercial strength in Southeast and North Asia, we are confident that we have chosen the right business partner to continue serving our patients, caring for our employees and making people happy.”
Bijay Singh, DKSH Executive Committee Member and Head of Global Healthcare Business Unit, added, “We are delighted to enter into this new partnership with Kyowa Kirin, especially as they have chosen DKSH as their regional partner for 6 markets. This collaboration reflects DKSH’s commitment to driving growth for its clients while pursuing its mission to provide better healthcare to all patients in its markets. By combining our expertise and resources with Kyowa Kirin’s outstanding brand, we believe we can offer more cost-effective and high-quality commercial access solutions that deliver outstanding patient outcomes and customer service.”
About Concord Kirin
Kyowa Kirin is dedicated to discovering novel medicines with life-changing value. As a global specialty pharmaceutical company headquartered in Japan, Kyowa Kirin has invested more than 70 years in drug discovery and biotechnology innovation and is currently working to design the next generation of antibodies, cell and gene therapies to help patients with serious or rare diseases. Our shared commitment to values, sustainability and making people smile unites us across its four regions – Japan, Asia Pacific, North America and EMEA/International. www.kyowakirin.com
About DKSH Holdings Limited
DKSH’s purpose is to enrich people’s lives. For nearly 160 years, DKSH has been committed to delivering growth for companies in Asia and beyond through its Healthcare, Consumer Goods, Performance Materials and Technologies business units. As a leading provider of market expansion services, DKSH offers sourcing, market insights, marketing and sales, e-commerce, distribution and logistics, and after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principle-based approach to responsible business. DKSH is listed on the Swiss Stock Exchange and operates in 36 markets with 29,040 experts and net sales of CHF 11.1 billion in 2023. As a strategic healthcare business partner, the DKSH Healthcare business unit distributes and commercializes pharmaceuticals, consumer health and over-the-counter products, and medical devices. The Healthcare business unit has approximately 8,140 experts and net sales of CHF 5.6 billion in 2023. www.dksh.com/hec
Source: DKSH Healthcare
Reporter: PR Wire
Editor: PR Wire
Copyright © ANTARA 2024
[ad_2]
Source link
